NY-VINCO-VENTURES
Vinco Ventures, Inc. (Nasdaq: BBIG) (“Vinco Ventures,” “Vinco,” or the “Company”), a digital media and content technologies holding company, today announced the appointment of Ted Farnsworth as co-Chief Executive Officer alongside Lisa King, current CEO of Vinco Ventures, effective June 8, 2022. Mr. Farnsworth and Ms. King will lead the Company as co-CEOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220714005566/en/
As Co-Founder and Chairman of ZASH Global Media and Entertainment (“ZASH”), Mr. Farnsworth was instrumental, along with Vinco and ZVV Media Partners (“ZVV”), in acquiring Lomotif and AdRizer, and has proven leadership and experience in the media industry. He has built many successful companies and is considered an expert in strategic development, marketing, public relations, consumer behavior and direct response marketing.
“I speak for myself and the entire Vinco team when I say how thrilled we are to welcome Ted to management in an official capacity as co-CEO,” said Lisa King, Co-CEO of Vinco Ventures. “Vinco and ZASH have begun to streamline our businesses. With Ted as co-CEO, together, we can more efficiently execute on our strategic growth plans with a clear understanding of our Company’s combined vision and plan.”
“I’ve worked alongside Vinco since the early days of ZASH and I am excited about the future. I am pleased to take on this role alongside Lisa, who was with me at ZASH when we acquired Lomotif,” said Ted Farnsworth, Co-CEO of Vinco Ventures. “As we continue moving forward and disrupting the media landscape, we remain focused on content, content, and content, and in turn, driving revenue through our portfolio of Vinco brands.”
A key component to Vinco’s growth strategy is Lomotif in combination with AdRizer and Mind Tank, our short-form video platform that drives user experiences with its user interface and patented editing tools. By utilizing Lomotif’s mobile or web-based platform, our ad and marketing platforms help drive engagement and grow revenue with premium content across the Vinco and ZASH ecosystem.
About Vinco Ventures
Vinco Ventures (Nasdaq: BBIG) is focused on the development of digital media and content technologies. Vinco Ventures’ consolidated subsidiary, ZVV Media Partners, LLC, a joint venture of Vinco Ventures and ZASH Global Media and Entertainment Corporation, has an 80% ownership interest in Lomotif Private Limited. Vinco Ventures owns a 100% ownership interest in AdRizer, LLC. For more information, please visit investors.vincoventures.com
.
Forward-Looking Statements and Disclaimers
This press release contains “forward-looking statements” as defined in the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which are based upon beliefs of, and information currently available to, Vinco Ventures’ management as well as estimates and assumptions made by Vinco Ventures’ management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “projected,” and other words or the negative of these terms and similar expressions as they relate to the applicable company or its management identify forward-looking statements. Such statements reflect the current view of Vinco Ventures with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to Vinco Ventures and its subsidiaries and consolidated variable interest entities including Lomotif, their industry, financial condition, operations and results of operations. Such factors include, but are not limited to, the expected risks and benefits from the proposed increase in Vinco Ventures’ authorized shares as described in our proxy statement, Vinco Ventures’ investments in ZVV Media Partners, LLC, Lomotif Private Limited, PZAJ Holdings, LLC and related growth initiatives and strategies such as the blended media, cross-platform distribution strategy, the expected benefits of Lomotif’s participation in and sponsorship of live entertainment events, the expected benefits from acquisition of AdRizer and planned integration of the AdRizer technology with Lomotif and Honey Badger and synergies between AdRizer, Lomotif and Honey Badger, the regulatory risks with the NFT and blockchain business lines and such other risks and uncertainties described more fully in documents filed by Vinco Ventures and Cryptyde with or furnished to the Securities and Exchange Commission, including the risk factors discussed in Vinco Ventures’ Annual Report on Form 10-K for the period ended December 31, 2021 filed on April 15, 2022 which is available at www.sec.gov . Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005566/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
